The efflux transporter ABCG2 maintains prostate stem cells

Molecular Cancer Research

Volumn 15, Issue 2, 2017, Pages 128-140

  Sabnis, Neha G ^a   Miller, Austin ^a   Titus, Mark A ^b   Huss, Wendy J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; ANDROGEN; ANDROGEN RECEPTOR; BREAST CANCER RESISTANCE PROTEIN; ENZALUTAMIDE; FUMITREMORGIN C; HYDROXYSTEROID DEHYDROGENASE; NOVOBIOCIN; TESTOSTERONE; 3-(6-ISOBUTYL-9-METHOXY-1,4-DIOXO-1,2,3,4,6,7,12,12A-OCTAHYDROPYRAZINO(1',2'-1,6)PYRIDO(3,4-B)INDOL-3-YL)PROPIONIC ACID TERT-BUTYL ESTER; AR PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; PIPERAZINEDIONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL LYSATE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CELL; PROSTATE STEM CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; THIN LAYER CHROMATOGRAPHY; TUMOR DIAGNOSIS; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CANCER STEM CELL; DRUG EFFECTS; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR CELL LINE; XENOGRAFT;

ANDROGENS; ANIMALS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; CELL LINE, TUMOR; DIKETOPIPERAZINES; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; TESTOSTERONE;

EID: 85011990264     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-16-0270-T     Document Type: Article

References (37)

1. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7:1028-1034.
2. Bhattacharya S, Das A, Mallya K, Ahmad I: Maintenance of retinal stem cells by Abcg2 is regulated by notch signaling. J Cell Sci 2007;120:2652-2662.
3. Martin CM, Meeson AP, Robertson SM, Hawke TJ, Richardson JA, Bates S, et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Dev Biol 2004;265:262-275.
4. Watanabe K, Nishida K, Yamato M, Umemoto T, Sumide T, Yamamoto K, et al. Human limbal epithelium contains side population cells expressing the ATP-binding cassette transporter ABCG2. FEBS Lett 2004;565:6-10.
5. Doyle MJ, Zhou S, Tanaka KK, Pisconti A, Farina NH, Sorrentino BP, et al. Abcg2 labels multiple cell types in skeletal muscle and participates in muscle regeneration. J Cell Biol 2011;195:147-163.
6. Apati A, Orban TI, Varga N, Nemeth A, Schamberger A, Krizsik V, et al. High level functional expression of the ABCG2 multidrug transporter in undifferentiated human embryonic stem cells. Biochim Biophys Acta 2008;1778:2700-2709.
7. Pfister O, Oikonomopoulos A, Sereti KI, Sohn RL, Cullen D, Fine GC, et al. Role of the ATP-binding cassette transporter Abcg2 in the phenotype and function of cardiac side population cells. Circ Res 2008;103:825-835.
8. Mathew G, Timm EA Jr, Sotomayor P, Godoy A, Montecinos VP, Smith GJ, et al. ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate. Cell Cycle 2009;8:1053-1061.
9. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res 2005;65:6640-6650.
10. Pascal LE, Oudes AJ, Petersen TW, Goo YA, Walashek LS, True LD, et al. Molecular and cellular characterization of ABCG2 in the prostate. BMC Urology 2007;7:6.
11. Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA. Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med 2011;17:657-664.
12. Colabufo NA, Pagliarulo V, Berardi F, Contino M, Inglese C, Niso M, et al. Bicalutamide failure in prostate cancer treatment: involvement of multi drug resistance proteins. Eur J Pharmacol 2008;601:38-42.
13. Foster BA, Gangavarapu KJ, Mathew G, Azabdaftari G, Morrison CD, Miller A, et al. Human prostate side population cells demonstrate stem cell properties in recombination with urogenital sinus mesenchyme. PLoS One 2013;8:e55062.
14. Tian J, Lee SO, Liang L, Luo J, Huang CK, Li L, et al. Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2′-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis. J Biol Chem 2012;287:39954-39966.
15. Chen X, Li Q, Liu X, Liu C, Liu R, Rycaj K, et al. Defining a population of stem-like human prostate cancer cells that can generate and propagate castration-resistant prostate cancer. Clin Cancer Res 2016;22:4505-16.
16. Ling MT, Chan KW, Choo CK. Androgen induces differentiation of a human papillomavirus 16 E6/E7 immortalized prostate epithelial cell line. J Endocrinol 2001;170:287-296.
17. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 1997;126:59-73.
18. Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, Yamamoto KR. Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev 2007;21:2005-2017.
19. Chen H, Libertini SJ, George M, Dandekar S, Tepper CG, Al-Bataina B, et al. Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocr Relat Cancer 2010;17:857-873.
20. Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 2012;31:4759-4767.
21. Liu LL, Xie N, Sun S, Plymate S, Mostaghel E, Dong X. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene 2014;33:3140-3150.
22. Ojo D, Lin X, Wong N, Gu Y, Tang D. Prostate cancer stem-like cells contribute to the development of castration-resistant prostate cancer. Cancers 2015;7:2290-2308.
23. Mostaghel EA. Steroid hormone synthetic pathways in prostate cancer. Transl Androl Urol 2013;2:212-227.
24. Chen Y, Bieber MM, Teng NN. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer. Mol Carcinog 2014;53:625-634.
25. Chau WK, Ip CK, Mak AS, Lai HC, Wong AS. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling. Oncogene 2013;32:2767-2781.
26. Kemppainen JA, Lane MV, Sar M, Wilson EM. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem 1992;267:968-974.
27. Heer R. Hunterian lecture. characterisation of human prostate epithelial progenitor differentiation in response to androgens. Ann R Coll Surg Engl 2011;93:424-428.
28. Rane JK, Pellacani D, Maitland NJ. Advanced prostate cancer - a case for adjuvant differentiation therapy. Nat Rev Urol 2012;9:595-602.
29. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344-3352.
30. Debruyne FJ, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F, et al. Liarozole - a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. Urology 1998;52:72-81.
31. Esquenet M, Swinnen JV, Heyns W, Verhoeven G. Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 1996;28:182-194.
32. Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model. J Cell Biochem 1998;69:271-281.
33. Robey RW, Ierano C, Zhan Z, Bates SE. The challenge of exploiting ABCG2 in the clinic. Curr Pharm Biotechnol 2011;12:595-608.
34. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 2002;1:417-425.
35. Lopez JP, Wang-Rodriguez J, Chang C, Chen JS, Pardo FS, Aguilera J, et al. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines. Arch Otolaryngol Head Neck Surg 2007;133:1022-1027.
36. Shishido Y, Ueno S, Yamazaki R, Nagaoka M, Matsuzaki T: ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan. Anticancer Res 2013;33:1379-1386.
37. Shukla S, Ohnuma S, Ambudkar SV. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets 2011;12:621-630.